Literature DB >> 11413298

YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.

P L Boyer1, H Q Gao, P K Clark, S G Sarafianos, E Arnold, S H Hughes.   

Abstract

When human immunodeficiency virus type 1 (HIV-1) is selected for resistance to 3TC, the methionine normally present at position 184 is replaced by valine or isoleucine. Position 184 is the X of the conserved YXDD motif; positions 185 and 186 form part of the triad of aspartic acids at the polymerase active site. Structural and biochemical analysis of 3TC-resistant HIV-1 reverse transcriptase (RT) led to a model in which a beta-branched amino acid at position 184 would act as a steric gate. Normal deoxynucleoside triphosphates (dNTPs) could still be incorporated; the oxathiolane ring of 3TCTP would clash with the beta branch of the amino acid at position 184. This model can also explain 3TC resistance in feline immunodeficiency virus and human hepatitis B virus. However, it has been reported (14) that murine leukemia viruses (MLVs) with valine (the amino acid present in the wild type), isoleucine, alanine, serine, or methionine at the X position of the YXDD motif are all resistant to 3TC. We prepared purified wild-type MLV RT and mutant MLV RTs with methionine, isoleucine, and alanine at the X position. The behavior of these RTs was compared to those of wild-type HIV-1 RT and of HIV-1 RT with alanine at the X position. If alanine is present at the X position, both MLV RT and HIV-1 RT are relatively resistant to 3TCTP in vitro. However, the mutant enzymes were impaired relative to their wild-type counterparts; there appears to be steric hindrance for both 3TCTP and normal dNTPs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413298      PMCID: PMC114354          DOI: 10.1128/JVI.75.14.6321-6328.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.

Authors:  S F Le Grice; F Grüninger-Leitch
Journal:  Eur J Biochem       Date:  1990-01-26

4.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

5.  In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.

Authors:  J K Wakefield; S A Jablonski; C D Morrow
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase.

Authors:  M M Georgiadis; S M Jessen; C M Ogata; A Telesnitsky; S P Goff; W A Hendrickson
Journal:  Structure       Date:  1995-09-15       Impact factor: 5.006

8.  Expression in Escherichia coli of a Moloney murine leukemia virus reverse transcriptase whose structure closely resembles the viral enzyme.

Authors:  A Hizi; S H Hughes
Journal:  Gene       Date:  1988-06-30       Impact factor: 3.688

9.  Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P L Boyer; J Ding; E Arnold; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.

Authors:  S F Le Grice; T Naas; B Wohlgensinger; O Schatz
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  13 in total

Review 1.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.

Authors:  Christine L Clouser; Colleen M Holtz; Mary Mullett; Daune L Crankshaw; Jacquie E Briggs; M Gerard O'Sullivan; Steven E Patterson; Louis M Mansky
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

3.  Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.

Authors:  Lu Gao; Mark Nils Hanson; Mini Balakrishnan; Paul L Boyer; Bernard P Roques; Stephen H Hughes; Baek Kim; Robert A Bambara
Journal:  J Biol Chem       Date:  2008-01-24       Impact factor: 5.157

4.  The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.

Authors:  Matthias Götte; Jason W Rausch; Bruno Marchand; Stefan Sarafianos; Stuart F J Le Grice
Journal:  Biochim Biophys Acta       Date:  2009-08-07

6.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

7.  Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

Authors:  Robert A Smith; Geoffrey S Gottlieb; A Dusty Miller
Journal:  Retrovirology       Date:  2010-08-31       Impact factor: 4.602

8.  Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity.

Authors:  Carolyn S Rinke; Paul L Boyer; Mark D Sullivan; Stephen H Hughes; Maxine L Linial
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.

Authors:  Emanuela Balestrieri; Giancarlo Forte; Claudia Matteucci; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.